Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma (ATHA) showcased preclinical data on its lead candidate, fosgonimeton (ATH-1017), at the AAIC 2022. The active metabolite, fosgo-AM, demonstrated neuroprotective effects in neuron cultures, enhancing neuron survival and neurite growth while mitigating neurotoxic impacts. Furthermore, novel orally bioavailable small molecules were shown to reverse memory deficits in animal models, promising for Alzheimer's treatment. These developments underline Athira's commitment to advancing its innovative therapies targeting neurodegenerative disorders.
Athira Pharma (NASDAQ: ATHA) announced its participation in the Alzheimer’s Association International Conference (AAIC) 2022, taking place from July 31 to August 4, 2022. Chief Medical Officer Hans Moebius will present results from the ACT-AD Phase 2 proof-of-concept study on fosgonimeton (ATH-1017) targeting mild-to-moderate Alzheimer’s patients. The conference will include discussions on novel Alzheimer’s treatments, with Athira presenting data on its small molecule HGF/MET platform aimed at neuroprotection and cognitive improvement.
Athira Pharma (ATHA) announced topline results from its ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The primary endpoint of statistically significant change in ERP P300 latency was not met, suggesting diminished effect when combined with standard-of-care AChEIs. However, a subgroup analysis indicated improved ERP P300 latency and cognitive performance in patients on fosgonimeton monotherapy compared to placebo. Fosgonimeton demonstrated a favorable safety profile, and insights gained will inform the ongoing LIFT-AD study.
Athira Pharma, Inc. (NASDAQ: ATHA) has established a Scientific Advisory Board (SAB) comprising leading experts in neurology and neurodegenerative diseases. The board, chaired by Athira's Chief Medical Officer, Dr. Hans Moebius, aims to provide strategic guidance for the development of Athira's novel small molecule compounds targeting conditions like Alzheimer’s and Parkinson’s disease. SAB members include prominent researchers from esteemed institutions, enhancing Athira’s capability in advancing its pipeline for neurological treatments.
Athira Pharma (NASDAQ: ATHA) announced that its shareholders have approved the election of three new independent directors: Joseph Edelman, John M. Fluke, Jr., and Grant Pickering. CEO Mark Litton expressed gratitude for shareholder support, emphasizing the directors' contributions during a crucial phase for the company. Athira will continue to advance its clinical trials, focusing on its lead drug candidate, fosgonimeton (ATH-1017), aiming to enhance shareholder value. The final voting results will be disclosed in a Form 8-K filing with the SEC.
Athira Pharma (NASDAQ: ATHA) has announced that its board recommends shareholders vote 'FOR' its three qualified director nominees on the WHITE proxy card. As Richard A. Kayne suspends his proxy contest, the board expresses gratitude for shareholder support and emphasizes its commitment to advancing Athira's strategy, especially with topline results from the Phase 2 ACT-AD study expected soon. The board believes it is well-equipped to drive company success, focusing on its developments in neurodegenerative diseases like Alzheimer’s and Parkinson’s.
On May 16, 2022, Ric Kayne, a shareholder of Athira Pharma (NASDAQ: ATHA), announced the suspension of his campaign for board election amid concerns about the company's future leadership and strategy for ATH-1017. Despite expressing optimism about the drug's potential, Kayne acknowledged that a close vote could lead to a contentious board dynamic. He emphasized shareholder engagement, urging them to voice their opinions, while asserting the need for enhanced clinical management in light of upcoming trial results.
Athira Pharma (NASDAQ: ATHA) announced promising preclinical findings for its small molecules, ATH-1018 and ATH-1019, targeting the HGF/MET signaling pathway. Presented at the 2022 Peripheral Nerve Society Annual Meeting, results showed significant improvement in pain-related behaviors in a diabetic neuropathy model. Notably, the effects persisted even after the compounds were cleared from plasma, suggesting long-lasting benefits. Athira aims to further evaluate these candidates to enhance its pipeline for treating diabetic neuropathy and other neurodegenerative conditions.
Athira Pharma (NASDAQ: ATHA) reported its Q1 2022 financial results and discussed progress in clinical studies, including the ACT-AD Phase 2 Alzheimer's study set to release topline data by the end of Q2 2022. The company increased R&D expenses to $14.5 million, up from $7.4 million in Q1 2021, and general and administrative costs surged to $8.9 million due to headcount growth. The net loss also widened to $21.0 million, or $0.56 per share, compared to $8.9 million, or $0.25 per share, in the same period last year.
Ric Kayne, a shareholder of Athira Pharma (NASDAQ: ATHA), has called for immediate changes to the board of directors, citing poor decision-making that has led to significant shareholder value destruction. In a letter to shareholders, Kayne outlines various missteps, including governance failures and management issues, urging shareholders to support his candidacy and that of George Bickerstaff at the upcoming annual meeting on May 19, 2022. He emphasizes the need for experienced leadership to restore confidence and improve the company's clinical trial oversight.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
